Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neuromyelitis Optica Spectrum Disorder: full-pipeline trial registry
5 of 7 indexed Neuromyelitis Optica Spectrum Disorder trials are currently recruiting.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 5 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Neuromyelitis Optica Spectrum Disorder: 7 US clinical trials tracked, 5 recruiting.
Neuromyelitis Optica Spectrum Disorder is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Amgen, running 3 of these trials.
Enrollment posture brief
Registry condition neuromyelitis-optica-spectrum-disorder
OPEN 5 | RECR 71% | LATE 2 | EARLY 2 | RANK #2497 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Endometrial Carcinoma (71% recruiting · 7 trials)
Neuromyelitis Optica Spectrum Disorder lists 5 open slots (71% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neuromyelitis Optica Spectrum Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neuromyelitis Optica Spectrum Disorder is recruiting above its size-band peers.
5 of 7 indexed trials (71.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neuromyelitis Optica Spectrum Disorder research.
Amgen accounts for 3 of 7 trials (42.9%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Neuromyelitis Optica Spectrum Disorder trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
Neuromyelitis Optica Spectrum Disorder splits between interventional and observational designs.
4 interventional and 3 observational studies make up this index (57.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
Alexion Pharmaceuticals
NCT05966467
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
Amgen
NCT05909761
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
Amgen
NCT05549258
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
Alexion Pharmaceuticals
NCT05346354
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
Hoffmann-La Roche
NCT05199688
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
University of Texas Southwestern Medical Center
NCT01623076
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Amgen
NCT06180278
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Neuromyelitis Optica Spectrum Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neuromyelitis Optica Spectrum Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neuromyelitis Optica Spectrum Disorder page
7 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Neuromyelitis Optica Spectrum Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amgen sponsors the most Neuromyelitis Optica Spectrum Disorder trials on record, review their full trial history before evaluating a specific study. See Amgen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neuromyelitis Optica Spectrum Disorder condition card totals 7 registered trials; most-linked intervention Inebilizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.